Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 2/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | PTPRA | P18433 | 1/20 | 0.39 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26242454 | 0.93 | DHODH (0.45) | PTPN1PTPRFDHODHRORCPTPRA | |
| SCHEMBL23791737 | 0.93 | IGF2BP2 (0.46) | PTPN1PTPRFDHODHRORCPTPRA | |
| SCHEMBL26241852 | 0.92 | MAPT (0.48) | DHODH | |
| SCHEMBL30173780 | 0.88 | DHODH (0.47) | PTPN1PTPRFDHODHRORCPTPRA | |
| SCHEMBL23782602 | 0.88 | DHODH (0.47) | PTPN1PTPRFDHODHRORCPTPRA | |
| SCHEMBL26242452 | 0.85 | PTPN1 (0.39) | PTPN1PTPRFDHODHRORC | |
| SCHEMBL26242060 | 0.81 | DHODH (0.40) | DHODHRORC | |
| SCHEMBL23782583 | 0.80 | DHODH (0.49) | DHODH | |
| SCHEMBL30173735 | 0.80 | DHODH (0.49) | DHODH | |
| SCHEMBL26242441 | 0.79 | DHODH (0.45) | PTPN1PTPRFDHODHPTPRAIGF2BP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | PTPN1 2774/4885PTPRF 1014/4885DHODH 3236/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | PTPN1 2774/4885PTPRF 1014/4885DHODH 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.